HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Brimonidine

HCID 2435
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
59803-98-4
Standard SMILES
Brc1c(NC2=NCCN2)ccc2nccnc12
InChIKey
XYLJNLCSTIOKRM-UHFFFAOYSA-N
Molecular formula
C11H10BrN5
Average molar mass
292.13 g/mol
Monoisotopic mass
291.01196

Overview

Brimonidine is a member of imidazoles, a secondary amine and a quinoxaline derivative. It has a role as an alpha-adrenergic agonist, an antihypertensive agent and an adrenergic agonist.

Names & identifiers

Preferred name
Brimonidine
IUPAC
5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine
English name
Brimonidine
Molecular formula
C11H10BrN5
Molecular weight
292.13

Names & synonyms

brimonidine59803-98-4Bromoxidine5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine5-Bromo-6-(2-imidazolin-2-ylamino)quinoxalinebrimonidinabrimonidinumUK-14304UK-1430418 FREE BASEBrimodineDTXSID3045221E6GNX3HHTE
Show more names
UK 14UBCHMG20RPS27ACS-1362UK 14,34UK-11957lk14304-18AGN-190342
AGN-190342 FREE BASENSC-318825CHEBI:3175DTXCID1025221RefChem:58237D11AX21S01EA05UK 14,304

Database identifiers

CAS
59803-98-4
PubChem CID
2435
DTXSID
DTXSID3045221
ChEMBL
CHEMBL844
ChEBI
CHEBI:3175
UNII
E6GNX3HHTE
EC Number
620-306-3
Nikkaji
J23.694B

Properties

Computed structural properties

XLogP
0.6
Topological polar surface area
62.2 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
3
Rotatable bonds
2
Heavy atoms
17
Formal charge
0
Complexity
308

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP1.7
Solubility · 2 items

1.54e-01 g/L

11.2 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Adrenergic alpha-2 Receptor Agonists; Antiglaucoma Agents

Pharmaceuticals

Melting Point207.5 °C
Physical DescriptionSolid
Dissociation Constants7.78

Physicochemical properties

Melting point
207.5 °C · 207.5 °C
Boiling point
432.6 · 432.6±55.0 °C(Predicted)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (100%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P270, P301+P316, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 44 reports by companies from 5 notifications to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (100%)

Toxicology

Exposure Routes · 1 item

Minimal systemic absorption occurs after ocular insertion. When the topical gel was applied to adult patients with facial erythema associated with rosacea, the plasma maximum concentration (Cmax) and area under the concentration-time curve (AUC) were 46 ± 62 pg/mL and 417 ± 264 pg.hr/mL, respectively. These values were reached on Day 15 of treatment.

Toxicity Summary · 1 item

Brimonidine is an alpha adrenergic receptor agonist (primarily alpha-2). It has a peak ocular hypotensive effect occurring at two hours post-dosing. Fluorophotometric studies in animals and humans suggest that Brimonidine has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. The topical gel reduces erythema through direct vasocontriction.

Signs and SymptomsOral LD<sub>50</sub> is 50 mg/kg in mice and 100 mg/kg in rats.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).

Chemistry & industry

Pharmacology

ATC Code · 6 items

S01EA05

S - Sensory organs

D - Dermatologicals

S - Sensory organs

QS - Sensory organs

QS - Sensory organs

Protein BindingThe protein binding of brimonidine has not been studied.
Pharmacodynamics · 1 item

Brimonidine is a highly selective alpha-2 adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenergic receptor than the alpha1-adrenergic receptor. This characteristic gives the drug some therapeutic advantages, since it reduces the risk of systemic side effects, such as systemic hypotension, bradycardia, and sedation. In addition, there is a reduction in the risk for developing alpha-1 mediated ocular unwanted effects, such as conjunctival blanching, mydriasis, and eyelid retraction. However, despite high alpha-2 receptor specificity, brimonidine may still produce alpha-1 adrenoceptor-mediated ocular effects, such as conjunctival vasoconstriction. Brimonidine has a peak ocular hypotensive effect occurring at two hours post-dosing. In a randomized, double-blind clinical study, ocular administration of 0.2% brimonidine in healthy volunteers resulted in a 23% reduction of mean intraocular pressure from baseline at 3 hours following administration. In comparative studies consisting of patients with open-angle glaucoma or ocular hypertension, the ocular hypotensive effect of brimonidine was maintained during treatment periods of up to 1 year. Brimonidine mediates vasoconstrictive effects and it was shown to exhibit anti-inflammatory properties in _ex vivo_ human skin model and _in vivo_ inflammation models. In a clinial trials consisting of adults with moderate to severe facial erythema of rosacea, brimonidine was shown to improve the extent of redness at 3 hours after application, compared to placebo. It was shown to be a potent vasoconstrictor of human subcutaneous vessels with a diameter of less than 200 µm. In _in vivo_ mouse inflammation models, brimonidine displayed anti-inflammatory properties by inhibiting edema. In a randomized, double-blind study, brimonidine reduced erythema for the 12 hours of the study in a dose-dependent manner. When adminsitered systemically, brimonidine was shown to cause cardiovascular effects by decreasing blood pressure, decreasing heart and respiratory rate, and prolonging the PR interval in the electrocardiogram. This is due to the targeting of adrenoceptors by the drug. Although the clinical significance has not been established, there is evidence that brimonidine exhibits neuroprotective activity in experimental models of cerebral ischemia and optic nerve injury. _In vitro_ studies show that brimonidine mediated protective effects on neuronal cells from kainate acid insult and on cultured retinal ganglion cells from glutamate-induced cytotoxicity, which is a possible mediator of secondary neuronal degeneration in human glaucoma. Neuroprotective actions of brimonidine were also demonstrated in rat models of acute retinal ischemia and chronic IOP elevation. It has been proposed that brimonidine may exert neuroprotective effects on the retina and optic nerve by enhancing intrinsic retinal ganglion cell survival mechanisms and/or induction of neuronal survival factors, such as bFGF. However, further investigations are needed to conclude on these possible therapeutic benefits of the drug.

Related reactions

21 records
New reaction record
HRID 430458 reaction equation
HRID 430458As reactant
HRID 493106 reaction equation
HRID 493106As reactant
HRID 535685 reaction equation
HRID 535685As product
HRID 654282 reaction equation
HRID 654282As product
HRID 741553 reaction equation
HRID 741553As reactant
HRID 802096 reaction equation
HRID 802096As product
HRID 861305 reaction equation
HRID 861305As reactant
HRID 863771 reaction equation
HRID 863771As reactant
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Density
1.82 · 1.82±0.1 g/cm3(Predicted)
storage temp.
2 · Keep in dark place,Sealed in dry,2-8°C
solubility
45 % · 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: <0.8 mg/mL
pka
7.69 · 7.69±0.10(Predicted)
form
powder to crystal
color
Light yellow to Amber to Dark green
biological source
mouse
Water Solubility
45 % · 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: DMSO: >6.5mg/mLethanol: H2O: insoluble
Merck
14 · 14,1375
InChI
InChI=1S/C11H10BrN5/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8/h1-4H,5-6H2,(H2,15,16,17)
InChIKey
XYLJNLCSTIOKRM-UHFFFAOYSA-N
SMILES
N1C2C(=C(Br)C(NC3NCCN=3)=CC=2)N=CC=1
CAS DataBase Reference
59803 · 59803-98-4(CAS DataBase Reference)
FDA UNII
6 GNX3HHTE · E6GNX3HHTE
ATC code
11 AX21,S01EA05,S01GA07 · D11AX21,S01EA05,S01GA07
Comptox DTXSID
3045221 · DTXSID3045221
UNSPSC Code
12352203 · 12352203
NACRES
77 · NA.77
Symbol(GHS)
6 · GHS06
Signal word
Danger
Hazard statements
301 · H301
Precautionary statements
301 · P301+P310
Hazard Codes
T
Risk Statements
25 · 25-36/37/38
Safety Statements
26 · 26-36-45
RIDADR
2811 · UN 2811 6.1/PG 3
WGK Germany
-
RTECS
1200000 · VD1200000
HazardClass
6.1 · 6.1
PackingGroup
Ⅲ
HS Code
2933290090 · 2933290090
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 Oral · Acute Tox. 3 Oral
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
Toxicity DataLD50: 50 mg/kg (oral, mice) LD50: 100 mg/kg (oral, rat)

Safety data

wgk
-
rtecs
VD1200000
ridadr
UN 2811 6.1/PG 3
hs_code
2933290090
risk_code
25-36/37/38
Signal word
Danger
Symbol(GHS)
GHS06
hazard_code
T
safety_code
26-36-45
hazard_class
6.1
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
Ⅲ
Hazard statements
H301
Hazard Classifications
Acute Tox. 3 Oral
Precautionary statements
P301+P310
Mechanism of Action · 1 item

In the eye, alpha-1 adrenoceptors play a role in vasoconstriction, mydriasis, eyelid retraction, and elevation of intraocular pressure (IOP) whereas alpha-2 adrenoceptors are responsible for IOP reduction via a complex Gi-coupled signaling cascade pathway. Activation of alpha-2 receptors leads to inhibition of adenylyl cyclase and reduction of cyclic AMP levels. As a result, there is a decrease in norpinephrine (NE) release at the synaptic junction, NE-induced stimulation of beta-2 adrenoceptors, and production of aqueous humor by the ciliary epithelium. An elevated IOP is the most significant risk factor for developing glaucomatous optic neuropathy, which is associated with progressive visual field loss and functional disability if left untreated. Regardless of the etiology of the disease, the aim of current therapies for glaucoma is to reduce IOP, as reduction of IOP significantly reduces the risk of progression of vision loss even when IOP is already within the normal range. When administered ophthalmically, brimonidine is rapidly absorbed into the eye, acts as an agonist at ocular alpha-2 adrenoceptors and lowers IOP via a dual mechanism of action. It is proposed that initial dosing of the drug causes a reduction in aqueous humour production and chronic dosing leads to an increase in uveoscleral outflow. Brimonidine does not affect episcleral venous pressure. By reducing IOP, brimonidine aims to reduce the likelihood of glaucomatous visual field loss in ocular hypertension, and slow the progression of visual field defect in established open-angle glaucoma. When applied topically on skin, brimonidine reduces erythema through direct vasocontriction of small arteries and veins. As brimonidine mediates a potent peripheral vasoconstrictive activity by selectively working on the alpha-2 adrenoceptors, the use of brimonidine is thought to be efficacious for the treatment of facial erythema of rosacea, which is thought to arise from vasomotor instability and abnormal vasodilation of the superficial cutaneous vasculature of the face.

Biological Half-LifeFollowing ocular administration of 0.2% brimonidine solution, the systemic half-life was approximately 3 hours.
Metabolism/Metabolites · 2 items

Brimonidine is reported to be metabolized in the cornea. Brominidine that reaches the systemic circulation upon topical administration undergoes extensive hepatic metabolism mediated by hepatic aldehyde oxidases.

Metabolized primarily by the liver. Route of Elimination: Urinary excretion is the major route of elimination of the drug and its metabolites. Half Life: 2 hours [ophthalmic solution]

FDA Pharmacological Classification · 6 items

E6GNX3HHTE

BRIMONIDINE

Mechanisms of Action [MoA] - Adrenergic alpha-Agonists

Established Pharmacologic Class [EPC] - alpha-Adrenergic Agonist

Brimonidine is an alpha-Adrenergic Agonist. The mechanism of action of brimonidine is as an Adrenergic alpha-Agonist.

BRIMONIDINE

MeSH Pharmacological Classification · 2 items

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.

Absorption, Distribution and Excretion · 4 items

Brimonidine readily penetrates the cornea following ocular administration to reach pharmacologically active concentrations in the aqueous humor and ciliary body, the putative sites of its IOP-lowering activity. Following ocular administration of 0.2% brimonidine solution, the peak plasma concentrations were achieved within 1 to 4 hours. In a clinical study of adult subjects with facial erythema of rosacea, brimonidine was cutaneously applied on facial skin in a repeated manner. While there was no drug accumulation in plasma, the highest peak plasma concentrations (Cmax) and AUC were 46 ± 62 pg/mL and 417 ± 264 pgxhr/mL, respectively.

Brimonidine and its metabolites are predominantly eliminated via urinary excretion, with 74% of the total dose being found in the urine.

The volume of distribution of brimonidine has not been established. In animal studies, brimonidine was shown to cross the placenta and enter into the fetal circulation to a limited extent. As its lipophilicity is relatively low, brimonidine is not reported to easily cross the blood-brain barrier.

The apparent clearance has not been studied. However, the systemic clearance of brimonidine is reported to be rapid. Approximately 87% of the total radioactive dose of brimonidine was shown to be eliminated within 120 hours following oral administration.

Cellular LocationsCytoplasm

Uses & manufacturing

Uses · 2 items

Use (kg; approx.) in Germany (2009): >10

The ophthalmic solution is indicated for patients with open-angle glaucoma or ocular hypertension to lower intraocular pressure. The topical gel is indicated for the treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years or older.

Use ClassificationPharmaceuticals
Applications · 4 items

DescriptionLaunched in the US for open-angle glaucoma and ocular hypertension, brimonidine is a relatively selective and potent α2a,-adrenergic agonist with low affinity for the imidazoline l1 receptor. Topical application reduces intraocular pressure. This bypasses any central hypotensive effects at the l1 receptor (which can also give rise to a decrease in blood pressure and heart rate) if given systemically, since topical application results in low plasma levels concomitant with rapid systemic elimination. Brimonidine can be prepared in a four-step sequence from 4-nitrophenylenediamine.

Usesα2-Adrenoceptor agonist. Antiglaucoma.

Usesa2-Adrenoceptor agonist. Antiglaucoma

Usescoronary vasodilator calcium ion influx inhibitor

Upstream & downstream products

Upstream raw materials

ThiophosgeneSodium bisulfite6-AminoquinoxalineEthylenediamine

Additional notes

DefinitionChEBI: Brimonidine is a quinoxaline derivative, a secondary amine and a member of imidazoles. It has a role as an adrenergic agonist, an antihypertensive agent and an alpha-adrenergic agonist.